Zimmer Biomet Holdings, Inc.’s Stock Price Skyrockets to $128.35, Marking a Robust 2.70% Increase

Zimmer Biomet Holdings, Inc. (ZBH)

128.35 USD +3.37 (+2.70%) Volume: 2.2M

Zimmer Biomet Holdings, Inc.’s stock price is currently standing at 128.35 USD, marking a positive trading session with a 2.70% increase. With a trading volume of 2.2M, ZBH has shown a promising year-to-date performance, with a percentage change of +5.60%.

Latest developments on Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings Inc., despite underperforming on Tuesday compared to competitors, has made significant strides in the stock market. The company has announced a $0.24 quarterly dividend for the first quarter of 2024, which is expected to boost investor confidence in the stock. Zimmer Biomet’s (ZBH) share price target is currently set at $136.04, offering a 9.4% upside potential. Additionally, large acquisitions of ZBH shares by HSBC Holdings PLC, Aigen Investment Management LP, and Grantham Mayo Van Otterloo & Co. LLC, further highlight the growing interest in Zimmer Biomet’s stock.

A look at Zimmer Biomet Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Zimmer Biomet Holdings is a company that makes medical equipment for people who need help with their bones, teeth, and spine. They make things like implants and cement for surgeries. They help patients all over the world.

Smartkarma Smart Scores give Zimmer Biomet Holdings a good outlook for the future. The company scores high in growth, which means they are expected to continue to do well. They also score high in value, which means they are a good deal for investors. However, their dividend and resilience scores are lower, which means they may not pay out as much money to investors and may not be as stable as other companies. Overall, Zimmer Biomet Holdings has a promising outlook, with a strong focus on growth and value.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma